# US 2024/0189407 A1 · Modified virus-like particles of bacteriophage ap205

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189407 A1
- Document ID: US20240189407A1
- Status: Published application
- Kind: A1
- Application number: 18/554,935
- Filed: 2022-04-11
- Published: 2024-06-13
- Earliest claimed: 2021-04-12
- Assignees: Saiba GmbH
- Applicants: Saiba AG
- Inventors: Kaspars TARS; Ilva LIEKNINA; Darja CERNOVA
- Web page: https://patentgrep.com/patent/US20240189407A1

## CPC

- C07K 16/12: against material from bacteria
- A61K 39/001134: {Transforming growth factor [TGF]}
- A61K 39/001138: {Tumor necrosis factors [TNF] or CD70}
- A61K 39/00114: {Interleukins [IL]}
- A61K 39/015: Hemosporidia antigens, e.g. Plasmodium antigens
- A61K 39/0225: {Spirochetes, e.g. Treponema, Leptospira, Borrelia}
- A61K 39/12: Viral antigens
- A61K 39/35: Allergens
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/081: DNA viruses
- C07K 16/102: Coronaviridae (F)
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- C07K 16/116: Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
- C07K 16/244: {Interleukins [IL]}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/6031: {Proteins}
- C12N 2710/12034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18571: Demonstrated in vivo effect
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20071: Demonstrated in vivo effect
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2795/18022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2795/18023: Virus like particles [VLP]
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a modified virus-like particle of RNA bacteriophage AP205 (AP205 VLP) comprising AP205 coat protein dimers to which antigenic polypeptides are fused at the N-terminus and/or at the C-terminus. The modified AP205 VLPs can be used as a platform, in particular for vaccine development, in generating immune responses against a variety of antigens.

## Claims

### Claim 1

A modified virus-like particle of RNA bacteriophage AP205 (AP205 VLP) comprising one or more fusion proteins, wherein said fusion protein comprises, preferably consists of,
(i) an AP205 coat protein dimer, wherein said AP205 coat protein dimer comprises a first AP205 polypeptide and a second AP205 polypeptide, wherein said first AP205 polypeptide is fused at its C-terminus either directly or via an amino acid spacer to the N-terminus of said second AP205 polypeptide, and wherein said first and said second AP205 polypeptide independently comprises
(a) an amino acid sequence of a coat protein of RNA bacteriophage AP205, or
(b) a mutated amino acid sequence, wherein said mutated amino acid sequence (b) and said amino acid sequence of said coat protein of RNA bacteriophage AP205 (a), have a sequence identity of at least 90%, preferably of at least 95%, further preferably of at least 98% and again more preferably of at least 99%; and
(ii) an antigenic polypeptide, wherein said antigenic polypeptide is fused to the N-terminus and/or the C-terminus of said AP205 coat protein dimer either directly or via an amino acid linker.

### Claim 2 (depends on 1)

The modified AP205 VLP of claim 1, said first and said second AP205 polypeptide independently comprises (a) an amino acid sequence of a coat protein of RNA bacteriophage AP205, or (b) a mutated amino acid sequence, wherein said mutated amino acid sequence and said amino acid sequence of a coat protein of RNA bacteriophage AP205 have a sequence identity at least 90%, wherein said coat protein of RNA bacteriophage AP205 comprises, preferably consists of, the amino acid sequence of SEQ ID NO: 26.

### Claim 3 (depends on 1, 2)

The modified AP205 VLP of claim 1 or claim 2, wherein said amino acid spacer as a length of at most 15 amino acids and is selected from the group consisting of:
(a.) a polyglycine linker (Gly)n of a length of n=2-10, preferably a length of n=2-5; and
(b.) a glycine-serine linker (GS-linker) comprising at least one glycine and at least one serine, wherein preferably said GS linker has an amino acid sequence of (GS)r(GsSw)t(GS)u with r=0 or 1, s=1-5, w=0 or 1; t=1-3 and u=0 or 1.

### Claim 4

The modified AP205 VLP of any one of the preceding claims, wherein said amino acid linker is selected from the group consisting of:
(a.) a polyglycine linker (Gly)n of a length of n=2-10, preferably a length of n=2-5; and
(b.) a glycine-serine linker (GS-linker) comprising at least one glycine and at least one serine, wherein preferably said GS linker has an amino acid sequence of (GS)r(GsSw)t(GS)u with r=0 or 1, s=1-5, w=0 or 1; t=1-3 and u=0 or 1; and wherein preferably said glycine-serine linker has a length of at most 15 amino acids;
(c.) an amino acid linker comprising at least one Gly, at least one Ser, and at least one amino acid selected from Thr, Ala, Lys, Asp and Glu, wherein said amino acid sequence has a length of at most 15 amino acids.

### Claim 5

The modified AP205 VLP of any one of the preceding claims, wherein said AP205 coat protein dimer comprises, preferably consists of, the amino sequence of SEQ ID NO: 7 or an amino acid sequence having a sequence identity of at least 90%, preferably of at least 95%, further preferably of at least 98% and again more preferably of at least 99% with said SEQ ID NO: 7.

### Claim 6

The modified AP205 VLP of any one of the preceding claims, wherein an antigenic polypeptide is fused directly or via an amino acid linker to the N-terminus of said AP205 coat protein dimer and an antigenic polypeptide is fused directly or via an amino acid linker to the C-terminus of said AP205 coat protein dimer.

### Claim 7

The modified AP205 VLP of any one of the preceding claims, wherein said modified AP205 VLP consists of said fusion proteins.

### Claim 8

The modified AP205 VLP of any one of the preceding claims, wherein said antigenic polypeptide is a polypeptide derived from the group consisting of: (a) allergens; (b) viruses; (c) bacteria; (d) parasites; (e) tumors; (f) self-molecules; (g) hormones; (h) growth factors; (i) cytokines; and (j) chemokines.

### Claim 9

The composition of any one of the preceding claims, wherein said antigenic polypeptide is selected from
(a) IL-17, and wherein preferably said antigenic polypeptide comprises, or preferably consists of, SEQ ID NO:36;
(b) IL-5, and wherein preferably said antigenic polypeptide comprises, or preferably consists of, any one the SEQ ID NO:37 to SEQ ID NO:42;
(c) IL-4, and wherein preferably said antigenic polypeptide comprises, or preferably consists of, any one the SEQ ID NO:43 to SEQ ID NO:45;
(d) IL-13, and wherein preferably said antigenic polypeptide comprises, or preferably consists of SEQ ID NO:49;
(e) IL-1α, and wherein preferably said antigenic polypeptide comprises, or preferably consists of, any one the SEQ ID NO:50 to SEQ ID NO:53;
(f) IL-33, and wherein preferably said antigenic polypeptide comprises, or preferably consists of, any one the SEQ ID NO:54 to SEQ ID NO:58;
(g) IL-25, and wherein preferably said antigenic polypeptide comprises, or preferably consists of, any one the SEQ ID NO:59 to SEQ ID NO:62;
(h) IL-1β, and wherein preferably said antigenic polypeptide comprises, or preferably consists of, any one the SEQ ID NO:63 to SEQ ID NO:67;
(i) IL-12/23;
(j) TNF-α;
(k) IL-31, wherein preferably said antigenic polypeptide comprises, or preferably consists of, any one the SEQ ID NO:68 to SEQ ID NO:71;
(l) thymic stromal lymphopoietin (TLSP), wherein preferably said antigenic polypeptide comprises, or preferably consists of, any one the SEQ ID NO:72 to SEQ ID NO:75;
(m) the dog allergen Can f1 or Can f2;
(n) myostatin, and wherein preferably said antigenic polypeptide comprises, or preferably consists of, SEQ ID NO:87;
(o) an antigenic polypeptide derived from Plasmodium falciparum or Plasmodium Vivax, and wherein preferably said antigenic polypeptide comprises, or preferably consists of, SEQ ID NO:88;
(p) CspZ protein from Borrelia burgdorferi, and wherein preferably said antigenic polypeptide comprises, or preferably consists of, SEQ ID NO:89 or SEQ ID NO:90;
(q) an antigenic polypeptide derived from RSV;
(r) Dengue viral antigenic polypeptide, wherein preferably said Dengue viral antigenic polypeptide comprises, or preferably consists of, SEQ ID NO:91 or SEQ ID NO:92;
(s) an antigenic polypeptide derived from a receptor binding domain (RBD) or a receptor binding motif (RBM) of a coronavirus (CoV), preferably of SARS-CoV-2, and wherein preferably said antigenic polypeptide comprises, or preferably consists of, any one the SEQ ID NO:94 to SEQ ID NO:97;
(t) an antigenic polypeptide derived from African Swine Fever;
(u) calcitonin gene-related peptide (CGRP);
(v) Amylin; and
(w) GnRH.

### Claim 10

The modified AP205 VLP of any one of the preceding claims, wherein said fusion protein is selected from the group consisting of SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:101, SEQ ID NO:106 and SEQ ID NO:110.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition comprising:
(a) the AP205 VLP of any one of claims 1 to 10; and
(b) a pharmaceutically acceptable carrier, diluent and/or excipient.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The modified AP205 VLP of any one of claims 1 to 10, or the pharmaceutical composition of claim 11 for use in a method of immunization an animal or a human comprising administering the modified AP205 VLP of any one of claims 1 to 10, or the pharmaceutical composition of claim 11 to said animal or human.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The modified AP205 VLP of any one of claims 1 to 10, or the pharmaceutical composition of claim 11 for use in a method for the treatment of a disease or disorder in an animal or human, wherein preferably said disease or disorder is selected from the group consisting of autoimmune disease, an inflammatory disease, an infectious disease or a cancer.

### Claim 14 (depends on 9, 13)

The modified AP205 VLP or the pharmaceutical composition for use of claim 13, wherein
a) said modified AP205 VLP is the modified AP205 VLP of any one of the claims 9(a) to 9(1), and wherein said disease or disorder is an inflammatory disease in an animal or human, and wherein preferably said inflammatory disease is selected from RA, MS, Psoriasis, ankylosing spondylitis, asthma, Crohns, Colitis, COPD, diabetes, neurodermatitis (allergic dermatitis);
b) said modified AP205 VLP is the modified AP205 VLP of claim 9(m), and wherein said disease or disorder is an allergy in a dog;
c) said modified AP205 VLP is the modified AP205 VLP of claim 9(0) for preventing or treating malaria;
d) said modified AP205 VLP is the modified AP205 VLP of claim 9(p), and wherein said disease or disorder is Lyme borreliosis;
e) said modified AP205 VLP is the modified AP205 VLP of claim 9(q) to 9(t), and wherein said disease or disorder is an infectious disease in an animal or human;
f) said modified AP205 VLP is the modified AP205 VLP of claim 9(u), and wherein said disease or disorder is migraine in an animal or human;
g) said modified AP205 VLP is the modified AP205 VLP of claim 9(v), and wherein said disease, disorder or condition is type II diabetes in an animal or human; or
h) said modified AP205 VLP is the modified AP205 VLP of claims 9(w), and wherein said disease or disorder is to lower testosterone levels in an animal or human.

### Claim 15

A modified virus-like particle of RNA bacteriophage AP205 (AP205 VLP) comprising one or more AP205 coat protein dimer, wherein said AP205 coat protein dimer comprises a first AP205 polypeptide and a second AP205 polypeptide, wherein said first AP205 polypeptide is fused at its C-terminus either directly or via an amino acid spacer to the N-terminus of said second AP205 polypeptide, and wherein said first and said second AP205 polypeptide independently comprises
(a) an amino acid sequence of a coat protein of RNA bacteriophage AP205, or
(b) a mutated amino acid sequence, wherein said mutated amino acid sequence (b) and said amino acid sequence of said coat protein of RNA bacteriophage AP205 (a), have a sequence identity of at least 90%, preferably of at least 95%, further preferably of at least 98% and again more preferably of at least 99%.
